Marksans Pharma has announced its audited consolidated financial results for the quarter and year ended March 31, 2026.
The company has reported significant growth in both total income and net profit for the period.
In the March 2026 quarter, Marksans Pharma's total income increased by 23.1% year-on-year (YoY) to ₹891.29 crore, compared to ₹723.80 crore in the same quarter of the previous year.
Sequentially, the total income rose by 15.1% from ₹774.57 crore in the December 2025 quarter.
The company's net profit for the March 2026 quarter surged by 64.3% YoY to ₹149.03 crore, up from ₹90.73 crore a year ago.
On a quarter-on-quarter (QoQ) basis, net profit increased by 31.1% from ₹113.69 crore in the December 2025 quarter.
For the financial year 2025-26, Marksans Pharma reported a total income of ₹3,033.47 crore, marking a 12.8% increase from ₹2,689.17 crore in the previous financial year.
The net profit for FY26 stood at ₹420.06 crore, reflecting a 9.79% rise from ₹382.62 crore in FY25.
The Board of Marksans Pharma has recommended a final dividend of ₹0.90 per equity share, with a face value of ₹1 per share, for the financial year 2025-26.
This dividend, representing 90%, is subject to approval by the members at the forthcoming Annual General Meeting (AGM). If approved, it will be credited or dispatched within 30 days from the date of the AGM.
As of May 26, 2026, at 1:09 PM, Marksans Pharma share price on NSE was trading at ₹238.62 up by 8.34% from the previous closing price.
Marksans Pharma has delivered a robust financial performance for Q4 and the full year FY26, with notable increases in both total income and net profit. The proposed dividend further underscores the company's commitment to returning value to its shareholders.
Want to track these market movements in Hindi? Visit Angel One News for daily updates and comprehensive share market news in Hindi. aa
Disclaimer: This blog has been written exclusively for educational purposes. The securities or companies mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks, read all the related documents carefully before investing.
Published on: May 26, 2026, 1:23 PM IST
Team Angel One
We're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
